{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:04:48Z","timestamp":1787958288454,"version":"build-2784847793"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009267","name":"College of Pharmacy and Health Sciences, Lipscomb University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010937","name":"St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioadv.2026.214921","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:00:28Z","timestamp":1777762828000},"page":"214921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ribociclib-loaded folic acid conjugated chitosan-polycaprolactone hybrid nanoparticles for the management of glioblastoma"],"prefix":"10.1016","volume":"186","author":[{"given":"Naveen","family":"Rajana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Ravula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mural","family":"Quadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Mokashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Asrarul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhwani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayssam","family":"Alkyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh K.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette C.","family":"Perron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Sanhueza Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioadv.2026.214921_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902971","article-title":"Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment","volume":"7","author":"Delgado-Mart\u00edn","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioadv.2026.214921_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clineuro.2018.04.028","article-title":"When did the glioblastoma start growing, and how much time can be gained from surgical resection? A model based on the pattern of glioblastoma growth in vivo","volume":"170","author":"Stensj\u00f8en","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.bioadv.2026.214921_bb0015","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/neuonc\/nov029","article-title":"Growth dynamics of untreated glioblastomas in vivo","volume":"17","author":"Stensj\u00f8en","year":"2015","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5306\/wjco.v5.i2.142","article-title":"Clinical outcomes following salvage gamma knife radiosurgery for recurrent glioblastoma","volume":"5","author":"Larson","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2019.110952","article-title":"Influence of synthesis methods on the internalization of fluorescent gold nanoparticles into glioblastoma stem-like cells","volume":"203","author":"Giesen","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bioadv.2026.214921_bb0030","doi-asserted-by":"crossref","DOI":"10.33448\/rsd-v10i11.19406","article-title":"Gold nanoparticles associated with temozolomide for glioblastoma Multiforme treatment","volume":"10","author":"Gialluca","year":"2021","journal-title":"Res. Soc. Dev."},{"key":"10.1016\/j.bioadv.2026.214921_bb0035","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/brainsci13111536","article-title":"Advances in glioblastoma therapy: an update on current approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.bioadv.2026.214921_bb0040","series-title":"StatPearls","article-title":"Nitrosoureas Toxicity","author":"Jackson","year":"2025"},{"key":"10.1016\/j.bioadv.2026.214921_bb0045","unstructured":"Bevacizumab (Avastin), (n.d.). https:\/\/www.cancerresearchuk.org\/about-cancer\/treatment\/drugs\/bevacizumab (accessed August 25, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111723","article-title":"Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: A systematic review and meta-analysis","volume":"11","author":"Kaka","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bioadv.2026.214921_bb0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14728222.2020.1762568","article-title":"Glioblastoma multiforme: novel therapeutic targets","volume":"24","author":"Muir","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioadv.2026.214921_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-012-1009-y","article-title":"Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme","volume":"111","author":"Muhic","year":"2013","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102317","article-title":"Natural compounds in glioblastoma therapy: Preclinical insights, mechanistic pathways, and outlook","volume":"13","author":"Zhai","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioadv.2026.214921_bb0070","first-page":"48","article-title":"Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions","volume":"3","author":"Juric","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bioadv.2026.214921_bb0080","unstructured":"Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma | J. Clin. Oncol., (n.d.). https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2011.35.5677 (accessed June 13, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077639","article-title":"PD-0332991, a CDK4\/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma","volume":"8","author":"Barton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2026.214921_bb0090","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with Temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.bioadv.2026.214921_bb0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-019-03864-9","article-title":"CNS penetration of the CDK4\/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors","volume":"84","author":"Patel","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0100","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","article-title":"Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma","volume":"19","author":"Rader","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioadv.2026.214921_bb0105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.drudis.2008.06.012","article-title":"Progress in the evaluation of CDK inhibitors as anti-tumor agents","volume":"13","author":"McInnes","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioadv.2026.214921_bb0110","doi-asserted-by":"crossref","first-page":"11501","DOI":"10.1073\/pnas.1001613107","article-title":"Pattern of retinoblastoma pathway inactivation dictates response to CDK4\/6 inhibition in GBM","volume":"107","author":"Wiedemeyer","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioadv.2026.214921_bb0115","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","article-title":"A phase I study of the CDK4\/6 inhibitor Ribociclib (LEE011) in pediatric patients with malignant Rhabdoid tumors, neuroblastoma, and other solid tumors","volume":"23","author":"Geoerger","year":"2017","journal-title":"Clin. Cancer res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bioadv.2026.214921_bb0120","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","article-title":"A phase 0 trial of Ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- and pharmacokinetic-guided expansion cohort","volume":"25","author":"Tien","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioadv.2026.214921_bb0125","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with Temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.bioadv.2026.214921_bb0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-019-03864-9","article-title":"CNS penetration of the CDK4\/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors","volume":"84","author":"Patel","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11060-019-03258-0","article-title":"Tumor pharmacokinetics and pharmacodynamics of the CDK4\/6 inhibitor ribociclib in patients with recurrent glioblastoma","volume":"144","author":"Miller","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0140","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/s41598-024-53151-8","article-title":"Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer","volume":"14","author":"Kappel","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioadv.2026.214921_bb0145","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-17-0803","article-title":"Combined CDK4\/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms","volume":"23","author":"Olmez","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioadv.2026.214921_bb0150","unstructured":"SJDAWN: Molecular-Based Therapy for Aggressive Brain and Spinal Cord Tumors in Children and Young Adults, St Jude Care Treat. (n.d.). https:\/\/www.stjude.org\/care-treatment\/clinical-trials\/sjdawn-brain-spinal-cord-tumors.html (accessed November 5, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0155","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.biomac.1c01076","article-title":"Amalgamated microneedle Array bearing Ribociclib-loaded Transfersomes eradicates breast Cancer via CD44 targeting","volume":"23","author":"Sharma","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bioadv.2026.214921_bb0160","unstructured":"Side Effects | mBC | KISQALI\u00ae (ribociclib), (n.d.). https:\/\/us.kisqali.com\/metastatic-breast-cancer\/about-kisqali\/understanding-and-managing-side-effects (accessed June 13, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0165","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.seminoncol.2018.03.006","article-title":"CDK4\/6 inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib","volume":"44","author":"Laderian","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106322","article-title":"Nanotechnology in glioblastoma therapy: advances in drug delivery systems and diagnostic approaches","volume":"102","author":"Qindeel","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106186","article-title":"Revolutionizing lung cancer treatment: nanotechnology-driven advances in targeted drug delivery and novel therapeutic strategies","volume":"101","author":"Shojaei","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0180","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/polym15071596","article-title":"Nanoparticles as drug delivery systems: a review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polymers"},{"key":"10.1016\/j.bioadv.2026.214921_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105980","article-title":"Targeted delivery of nanomedicines to glioblastoma: overcoming the clinical barrier","volume":"99","author":"Nayak","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0190","series-title":"Ligands Target","first-page":"159","article-title":"Chapter 4 - ligand conjugation strategies","author":"Kumari","year":"2025"},{"key":"10.1016\/j.bioadv.2026.214921_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.131491","article-title":"Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine \u2013 development & characterization in physiologically relevant 3D tissue models","volume":"267","author":"Gadhave","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.132526","article-title":"Chitosan\/bovine serum albumin layer-by-layer assembled particles for non-invasive inhaled drug delivery to the lungs","volume":"271","author":"Chauhan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128821","article-title":"Design, development, and evaluation of CDK-4\/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer","volume":"258","author":"Pooja","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.msec.2015.08.006","article-title":"IR 820 dye encapsulated in polycaprolactone glycol chitosan: Poloxamer blend nanoparticles for photo immunotherapy for breast cancer","volume":"57","author":"Kumar","year":"2015","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bioadv.2026.214921_bb0215","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ijbiomac.2021.05.163","article-title":"Preparation and characterization of polycaprolactone\/chitosan-g-polycaprolactone\/hydroxyapatite electrospun nanocomposite scaffolds for bone tissue engineering","volume":"182","author":"Shirzaei Sani","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0220","doi-asserted-by":"crossref","first-page":"56162","DOI":"10.1039\/C5RA05997F","article-title":"IR 820 stabilized multifunctional polycaprolactone glycol chitosan composite nanoparticles for cancer therapy","volume":"5","author":"Kumar","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioadv.2026.214921_bb0225","unstructured":"Lian: Protocol for primary microglial culture preparation - Google Scholar, (n.d.). https:\/\/scholar.google.com\/scholar_lookup?title=Protocol%20for%20Primary%20Microglial%20Culture%20Preparation&publication_year=2016&author=H.%20Lian&author=E.%20Roy&author=H.%20Zheng (accessed July 10, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0230","unstructured":"Design of experiment-oriented development and validation of novel bioanalytical reverse phase high performance liquid chromatography method of Palbociclib in rat plasma and tissues, and its application in pharmacokinetic studies - Rajana - 2024 - Biomed. Chromatogr. - Wiley Online Library, (n.d.). https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/bmc.5815 (accessed June 13, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127142","article-title":"Folic acid-chitosan functionalized polymeric nanocarriers to treat colon cancer","volume":"253","author":"Bhaskaran","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0240","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.ijbiomac.2020.09.185","article-title":"Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: in vitro, ex vivo and toxicity assessments","volume":"163","author":"Shahab","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123006","article-title":"Investigating the effectiveness of Difluprednate-loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery","volume":"640","author":"Kaviarasi","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2026.214921_bb0250","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/pharmaceutics17050540","article-title":"An inhaled Nanoemulsion encapsulating a herbal drug for non-small cell lung Cancer (NSCLC) treatment","volume":"17","author":"Quadros","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2026.214921_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106588","article-title":"Transferrin-conjugated polymeric nanoparticles for receptor-mediated delivery of resveratrol-cyclodextrin complex in non-small cell lung cancer (NSCLC) cells","volume":"105","author":"Wang","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125632","article-title":"Quality by design enabled development & in-vitro assessment of a Nanoemulgel formulation for nose-to-brain delivery of Nintedanib for glioblastoma multiforme treatment","volume":"676","author":"Gadhave","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2026.214921_bb0265","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1021\/acsomega.0c05500","article-title":"Folate receptors\u2019 expression in gliomas may possess potential nanoparticle-based drug delivery opportunities","volume":"6","author":"McCord","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioadv.2026.214921_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123787","article-title":"Targeted delivery and apoptosis induction of CDK-4\/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells","volume":"651","author":"Rajana","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"16","key":"10.1016\/j.bioadv.2026.214921_bb0275","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1039\/D2BM00022A","article-title":"Development of gelatin methacrylate (GelMa) hydrogels for versatile intracavitary applications","volume":"10","author":"Kulkarni","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bioadv.2026.214921_bb0280","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcyt.2023.11.008","article-title":"Assessment and comparison of viability assays for cellular products","volume":"26","author":"Cai","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bioadv.2026.214921_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140316","article-title":"Fabrication and characterization of teriflunomide-loaded chondroitin sulfate hybridized zein nanoparticles for the management of triple negative breast cancer","volume":"300","author":"Rajana","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.brainres.2006.10.083","article-title":"Tight junction protein expression and barrier properties of immortalized mouse BRAIN MICROVESSEL endothelial cells","volume":"1130","author":"Brown","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.bioadv.2026.214921_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134765","article-title":"A triple culture model of the blood-brain barrier using porcine brain endothelial cells, astrocytes and pericytes","volume":"10","author":"Thomsen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2026.214921_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108602","article-title":"Ribociclib, a selective cyclin D kinase 4\/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo","volume":"112","author":"Xiong","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioadv.2026.214921_bb0305","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijbiomac.2020.05.146","article-title":"Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma \u2013 a rare thoracic cancer","volume":"160","author":"Shukla","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0310","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijbiomac.2021.12.070","article-title":"Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines","volume":"199","author":"Geethakumari","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0315","doi-asserted-by":"crossref","DOI":"10.1088\/1757-899X\/311\/1\/012024","article-title":"Effect of tween 80 on nanoparticle preparation of modified chitosan for targeted delivery of combination doxorubicin and curcumin analogue","volume":"311","author":"Sukmawati","year":"2018","journal-title":"IOP Conf. Ser.: Mater. Sci. Eng."},{"key":"10.1016\/j.bioadv.2026.214921_bb0320","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1021\/acs.cgd.3c01460","article-title":"Enhanced dissolution and diffusion of Ribociclib by salt formation with Fluorobenzoic acid Coformers","volume":"24","author":"Sangwan","year":"2024","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.bioadv.2026.214921_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2022.110394","article-title":"3D-printed polycaprolactone-chitosan based drug delivery implants for personalized administration","volume":"214","author":"Yang","year":"2022","journal-title":"Mater. Des."},{"key":"10.1016\/j.bioadv.2026.214921_bb0330","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2011.03.051","article-title":"Higuchi equation: derivation, applications, use and misuse","volume":"418","author":"Siepmann","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2026.214921_bb0335","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1021\/acsomega.0c05500","article-title":"Folate receptors\u2019 expression in gliomas may possess potential nanoparticle-based drug delivery opportunities","volume":"6","author":"McCord","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioadv.2026.214921_bb0340","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: the mechanism of action may not be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioadv.2026.214921_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213672","article-title":"Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy","volume":"155","author":"Sharma","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.bioadv.2026.214921_bb0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1535-6108(02)00241-6","article-title":"Apoptosis-targeted therapies for cancer","volume":"3","author":"Reed","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioadv.2026.214921_bb0355","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ceo.12397","article-title":"Expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma","volume":"43","author":"Singh","year":"2015","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioadv.2026.214921_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2025.04.001","article-title":"The RB protein: more than a sentry of cell cycle entry","author":"Thangavelu","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bioadv.2026.214921_bb0370","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","article-title":"Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies","volume":"61","author":"Agnihotri","year":"2013","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.bioadv.2026.214921_bb0375","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-019-03864-9","article-title":"CNS penetration of the CDK4\/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors","volume":"84","author":"Patel","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0380","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1007\/s12668-024-01593-9","article-title":"Synthesis of Nanocarrier based on chitosan\/agarose biopolymers containing carbon quantum dot doped titanium dioxide for targeted delivery of 5-fluorouracil for brain Cancer treatment","volume":"14","author":"Masnavi","year":"2024","journal-title":"BioNanoScience"},{"key":"10.1016\/j.bioadv.2026.214921_bb0385","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.biomaterials.2006.12.018","article-title":"Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery","volume":"28","author":"Zhang","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2026.214921_bb0390","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00289-011-0674-x","article-title":"Preparation, characterization, and in vitro release of folic acid-conjugated chitosan nanoparticles loaded with methotrexate for targeted delivery","volume":"68","author":"Ji","year":"2012","journal-title":"Polym. Bull."},{"key":"10.1016\/j.bioadv.2026.214921_bb0395","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.ijbiomac.2020.09.185","article-title":"Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: in vitro, ex vivo and toxicity assessments","volume":"163","author":"Shahab","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0400","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.ijbiomac.2020.09.185","article-title":"Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: in vitro, ex vivo and toxicity assessments","volume":"163","author":"Shahab","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2024.100215","article-title":"Fundamentals behind the success of nanotechnology in cancer treatment and diagnosis","volume":"20","author":"Chowdhury","year":"2024","journal-title":"OpenNano"},{"key":"10.1016\/j.bioadv.2026.214921_bb0410","unstructured":"Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats: Nanomedicine: Vol 3, No 5 - Get Access, (n.d.). https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/17435889.3.5.703 (accessed June 13, 2025)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124799","article-title":"Effects of nanoparticle size, shape, and zeta potential on drug delivery","volume":"666","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214921_bb0420","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1007\/s10570-019-02357-5","article-title":"pH-responsive cellulose\u2013chitosan nanocomposite films with slow release of chitosan","volume":"26","author":"Yang","year":"2019","journal-title":"Cellulose"},{"key":"10.1016\/j.bioadv.2026.214921_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122951","article-title":"Meta-analysis of material properties influencing nanoparticle plasma pharmacokinetics","volume":"639","author":"Macedo","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2026.214921_bb0430","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.biomac.1c01076","article-title":"Amalgamated microneedle Array bearing Ribociclib-loaded Transfersomes eradicates breast Cancer via CD44 targeting","volume":"23","author":"Sharma","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bioadv.2026.214921_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213672","article-title":"Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy","volume":"155","author":"Sharma","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.bioadv.2026.214921_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioadv.2026.214921_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880153","article-title":"Combining a CDK4\/6 inhibitor with Pemetrexed inhibits cell proliferation and metastasis in human lung adenocarcinoma","volume":"12","author":"Ke","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0450","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coche.2020.07.002","article-title":"In vitro models of the blood-brain barrier: building in physiological complexity","volume":"30","author":"Katt","year":"2020","journal-title":"Curr. Opin. Chem. Eng."},{"key":"10.1016\/j.bioadv.2026.214921_bb0455","article-title":"Comparative studies between the murine immortalized brain endothelial cell line (bEnd.3) and induced pluripotent stem cell-derived human brain endothelial cells for paracellular transport","volume":"17","author":"Sun","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2026.214921_bb0460","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214921_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-13721-w","article-title":"Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma","volume":"15","author":"Kurawattimath","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioadv.2026.214921_bb0470","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1016\/j.biomaterials.2012.07.046","article-title":"Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles","volume":"33","author":"Xin","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2026.214921_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/polym15193890","article-title":"Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone nanoparticles coated with Chitosan for Nose-to-brain delivery: in vitro and in vivo studies","volume":"15","author":"Badran","year":"2023","journal-title":"Polymers"},{"key":"10.1016\/j.bioadv.2026.214921_bb0480","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3762\/bjnano.8.144","article-title":"Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment","volume":"8","year":"2017","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0485","unstructured":"Surface-Modified Biobased Polymeric Nanoparticles for Dual Delivery of Doxorubicin and Gefitinib in Glioma Cell Lines | ACS Omega, (n.d.). https:\/\/pubs.acs.org\/doi\/10.1021\/acsomega.3c01375 (accessed February 9, 2026)."},{"key":"10.1016\/j.bioadv.2026.214921_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106025","article-title":"Folate receptor-targeted indomethacin-loaded gold nanoparticles enhance drug chemotherapeutic efficacy in glioblastoma cells and spheroids","volume":"100","author":"Y\u00fccel","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bioadv.2026.214921_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091116","article-title":"Targeted fluoxetine delivery using folic acid-modified PLGA nanoparticles for selective uptake by glioblastoma cells","volume":"17","author":"Ramalho","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950826002190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950826002190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:49:40Z","timestamp":1779450580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950826002190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":98,"alternative-id":["S2772950826002190"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2026.214921","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ribociclib-loaded folic acid conjugated chitosan-polycaprolactone hybrid nanoparticles for the management of glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2026.214921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"214921"}}